A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

(2016) Max Schreuer et al.   Journal of Translational Medicine

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma

(2015) S. D. Bradley et al.   Cancer Immunology Research

Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors

(2014) M. F. Sanmamed et al.   CLINICAL CHEMISTRY

Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma

(2014) D. J. Panka et al.   MOLECULAR CANCER THERAPEUTICS

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRAF Inhibition Alleviates Immune Suppression in Murine Autochthonous Melanoma

(2014) S. M. Steinberg et al.   Cancer Immunology Research

Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program

(2014) Roxanne Payne et al.   Journal for ImmunoTherapy of Cancer

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Resistance to BRAF-targeted therapy in melanoma

(2013) Ryan J. Sullivan et al.   EUROPEAN JOURNAL OF CANCER

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes

(2013) Zachary A Cooper et al.   OncoImmunology

Characterizing the Clinical Benefit of Ipilimumab in Patients Who Progressed on High-dose IL-2

(2012) Richard W. Joseph et al.   JOURNAL OF IMMUNOTHERAPY

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma

(2011) Richard W. Joseph et al.   JOURNAL OF IMMUNOTHERAPY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA